EFG International AG Makes New Investment in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• EFG International AG acquired a new 46,552-share stake in Tarsus Pharmaceuticals during the second quarter, valued at approximately $2.93 million and representing about 0.11% of the company. Institutional investors collectively own 90.01% of Tarsus.
• Tarsus shares recently traded at $70.65, while the company reported a quarterly loss of $0.43 per share, missing estimates by $0.24, despite revenue of $173.91 million exceeding expectations.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $90.50, although insiders sold 39,850 shares worth approximately $2.45 million during the latest quarter.

EFG International AG bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 46,552 shares of the company's stock, valued at approximately $2,932,000. EFG International AG owned approximately 0.11% of Tarsus Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Parallel Advisors LLC raised its stake in Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after acquiring an additional 291 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank grew its holdings in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company's stock worth $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC grew its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company's stock worth $74,000 after purchasing an additional 468 shares during the last quarter. Finally, State of Wyoming acquired a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $103,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Trading Down 1.1%

NASDAQ TARS opened at $70.65 on Thursday. The firm's fifty day moving average is $64.05 and its two-hundred day moving average is $65.24. Tarsus Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The firm has a market cap of $3.10 billion, a PE ratio of -64.82 and a beta of 0.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The business had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

TARS has been the subject of several research reports. Guggenheim reduced their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a report on Tuesday, July 21st. Mizuho cut their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $90.50.

Insider Buying and Selling

In other news, Director William J. Phd Link sold 12,500 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the transaction, the director owned 106,786 shares of the company's stock, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the transaction, the director directly owned 2,233 shares in the company, valued at approximately $138,624.64. The trade was a 56.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,850 shares of company stock valued at $2,452,821 in the last quarter. 9.64% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source